April 11, 2022
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
Moderna, Inc. (NASDAQ:MRNA), has announced the first participants have been dosed in the Phase 1/2 study of the company’s seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030.